PROTEIN-COMPOSITION OF THE HEPATITIS-B VIRUS-E ANTIGEN IN THE NATURAL COURSE OF DISEASE AND FOLLOWING INTERFERON THERAPY

被引:4
作者
CAMPILLO, ML [1 ]
QUIROGA, JA [1 ]
BARTOLOME, J [1 ]
MORALEDA, G [1 ]
CASTILLO, I [1 ]
CARRENO, V [1 ]
机构
[1] FDN JIMENEZ DIAZ,DEPT GASTROENTEROL,HEPATOL UNIT,E-28040 MADRID,SPAIN
关键词
D O I
10.1128/JCM.30.5.1256-1261.1992
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The protein composition of hepatitis B virus (HBV) e antigen (HBeAg) in serum was analyzed for 63 viremic patients with chronic HBV and found to consist of polypeptides with molecular masses of 16, 18, and 20 kDa (P16e, P18e, and P20e, respectively). Several experiments demonstrated their viral nature and HBeAg specificity and that P16e occurs either in free soluble form or as aggregates or immunocomplexes, while P18e and P20e occur essentially as immunocomplexes. Of 63 patients, 45 (71%) had P16e, P18e, and P20e, and the remaining 18 (29%) had only P16e. During the natural history of the disease, spontaneous clearance of HBV DNA and HBeAg took place only in six of nine (67%) patients with the three HBe polypeptides but in none of the five patients having P16e alone (P < 0.05). Similarly, 22 of 23 (96%) patients responding to interferon therapy had P16e, P18e, and P20e, but these polypeptides occurred in only 14 of 26 (54%) nonresponder patients (P < 0.001). Following the loss of HBV DNA and HBeAg, before the development of anti-HBe, the only HBe species detected were P18e and P20e, but these became no longer detectable after complete normalization of liver function tests. Therefore, persistence of P16e represents a failure to recover from HBV, and the appearance of HBe polypeptides P18e and P20e is associated with virus clearance and a favorable outcome of the disease.
引用
收藏
页码:1256 / 1261
页数:6
相关论文
共 27 条
[1]  
BABA K, 1986, CLIN EXP IMMUNOL, V64, P295
[2]   AN ASSAY FOR THE DETECTION OF THE DNA GENOME OF HEPATITIS-B VIRUS IN SERUM [J].
BERNINGER, M ;
HAMMER, M ;
HOYER, B ;
GERIN, JL .
JOURNAL OF MEDICAL VIROLOGY, 1982, 9 (01) :57-68
[3]   QUANTITATION OF HEPATITIS-B VIRUS (HBV) CORE ANTIGEN IN SERUM IN THE PRESENCE OF ANTIBODIES TO HBV CORE ANTIGEN - COMPARISON WITH ASSAYS OF SERUM HBV DNA, DNA-POLYMERASE, AND HBV E-ANTIGEN [J].
BREDEHORST, R ;
VONWULFFEN, H ;
GRANATO, C .
JOURNAL OF CLINICAL MICROBIOLOGY, 1985, 21 (04) :593-598
[4]   FORMATION OF TRANSMEMBRANEOUS HEPATITIS-B E-ANTIGEN BY COTRANSLATIONAL INVITRO PROCESSING OF THE VIRAL PRECORE PROTEIN [J].
BRUSS, V ;
GERLICH, WH .
VIROLOGY, 1988, 163 (02) :268-275
[5]  
CARRENO V, 1987, LIVER, V7, P325
[6]  
CASTILLO I, 1990, LIVER, V10, P79
[7]   THE MOLECULAR-BIOLOGY OF THE HEPATITIS-B VIRUSES [J].
GANEM, D ;
VARMUS, HE .
ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :651-693
[8]   TARGETING OF THE HEPATITIS-B VIRUS PRECORE PROTEIN TO THE ENDOPLASMIC-RETICULUM MEMBRANE - AFTER SIGNAL PEPTIDE CLEAVAGE TRANSLOCATION CAN BE ABORTED AND THE PRODUCT RELEASED INTO THE CYTOPLASM [J].
GARCIA, PD ;
OU, JH ;
RUTTER, WJ ;
WALTER, P .
JOURNAL OF CELL BIOLOGY, 1988, 106 (04) :1093-1104
[9]  
Harlow E., 1988, ANTIBODIES LAB MANNU, P471
[10]   RANDOMIZED, CONTROLLED TRIAL OF RECOMBINANT HUMAN ALPHA-INTERFERON IN PATIENTS WITH CHRONIC HEPATITIS-B [J].
HOOFNAGLE, JH ;
PETERS, M ;
MULLEN, KD ;
JONES, DB ;
RUSTGI, V ;
DIBISCEGLIE, A ;
HALLAHAN, C ;
PARK, Y ;
MESCHIEVITZ, C ;
JONES, EA .
GASTROENTEROLOGY, 1988, 95 (05) :1318-1325